In Table 4, compared with the normal sleep group, the sleep disorder group had a significantly higher proportion of patients with poorly differentiated tumor differentiation (P < 0.001), tumor stage IV (P = 0.032), and EGFR gene mutation (P = 0.037), as well as significantly elevated levels of peripheral carcinoembryonic antigen (P < 0.001), cytokeratin 19 fragment (P < 0.001), neuron-specific enolase (P < 0.001), lactate dehydrogenase (P < 0.001), and tumor mutation burden (P < 0.001). Here, ENO2 is linked to sleep disorder.